Business Wire

Scientist.com Partners with UK-based BioIndustry Association (BIA)

Del

Scientist.com, the world’s largest marketplace for outsourced scientific services, today announced a partnership with the BioIndustry Association (BIA), the UK’s national trade association for innovative bioscience enterprises. The partnership will allow BIA members to access the Scientist.com marketplace, connect with global experts and purchase custom research services required for drug R&D.

“We are proud to make the services offered on Scientist.com’s award-winning marketplace available to BIA members that participate in our BIA Business Solutions Programme,” stated BIA CEO, Steve Bates. “Our dedicated BIA marketplace will help our members save time and money by streamlining the entire R&D process. It will provide access to the latest innovation and a global platform for members to showcase their world leading services.”

The BIA plays an integral role in the development and commercialisation of UK-based therapeutics and works to influence government to ensure the best possible biotech ecosystem for companies to grow and scale in the UK. BIA members will now receive the added benefit of an online marketplace to meet their sourcing needs. Scientist.com brings together over 2,600 pre-qualified CROs onto one digital platform and makes it easy for researchers to connect with technical experts, design custom experiments and then purchase without legal or finance delay.

“The BIA Business Solutions Programme is the UK’s largest cost-savings program in the biosciences sector, helping its member companies get volume-based discounts, competitive terms and other benefits on research products and services,” said Kevin Lustig, PhD, Scientist.com’s CEO and Founder. “Scientist.com enables BIA member scientists in the UK to connect with thousands of pre-qualified contract research organizations (CROs) and rapidly create and purchase custom research services.”

Learn more about Scientist.com at UK Bioscience Forum 2018, which is scheduled for Thursday 18 October at the Queen Elizabeth II Conference Centre, Westminster, London.

About Scientist.com

Scientist.com is the world's leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, many top biotech companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo among others. Visit scientist.com to learn more.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook, Google+ and Instagram.

About the BIA

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org and twitter.com/BIA_UK

Contact information

Scientist.com
Sean Preci
Director of Communications
+1 858 455-1300 ext. 401
marketing@scientist.com
or
BioIndustry Association
Ed Sexton
Senior Communications Manager
02076302196
esexton@bioindustry.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Brightline Initiative Announces Strategic Partnership with NetEase11.12.2018 13:00Pressemelding

The Brightline Initiative announced today that NetEase (网易) joined its coalition as first founding member from the Asia region to help address the growing challenges of strategy implementation leveraging on insight and learnings from Chinese technology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005409/en/ Brightline Initiative Announces Strategic Partnership with NetEase (Photo: Business Wire) Launched in early 2017, the Brightline™ Initiative is a coalition, led by the Project Management Institute together with leading global organizations, dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery. Brightline focuses its work on three key areas: Thought and Practice Leadership, Networking and Capability Building. NetEase Hangzhou Research Institute Chief Executive Chen Gang said, “Historically NetEase has been paying close attention on strategy design

Quotient Sciences Conducts Integrated Translational Pharmaceutics® Program in U.S. with Druggability Technologies11.12.2018 13:00Pressemelding

Quotient Sciences, a leading drug development services organization, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities. Within the program of work, DRGT is accessing Quotient’s unique Translational Pharmaceutics platform. This involves the development of amorphous spray-dried formulations and GMP clinical trial manufacturing in Philadelphia followed by clinical dosing and taste assessment at Quotient’s clinical pharmacology unit in Miami. The program is fully adaptive, which will enable DRGT to optimize the drug product in response to emerging clinical data. Quotient will then seamlessly scale up the selected

AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition11.12.2018 11:28Pressemelding

AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the US. AMRA® Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements. AMRA is the first in the world to transform MR-images from a 6-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status. “We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure,” stated Eric Converse, CEO of

Acuris Risk Intelligence Celebrates 350 Direct Customers and Wins Compliance Awards11.12.2018 11:00Pressemelding

Acuris Risk Intelligence, a trusted and independent provider of data intelligence for Anti-Money Laundering, Third Party Risk and Cyber Security professionals, today announces that it now serves 350 direct customers worldwide, helping them to mitigate risk and effectively comply with regulations. This significant milestone nearly doubles its direct client base compared to this time last year and is only two months since the relaunch of the brand, formerly known as C6. Whilst the business has been successful since its inception in 2004 in selling its data via major channel partners, this is a noteworthy milestone as it reflects the success of focusing on direct customer outreach. The business continues to work with some of the biggest compliance platforms in the world as an integrated provider. Acuris Risk Intelligence has also won FinTech/RegTech Rising Star and Best Financial Crime Intelligence Data at The Compliance Register Platinum Awards 2018 as well as executing a successful expa

Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia11.12.2018 10:30Pressemelding

Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”). After Slovakia, in early 2019 Evopharm will expand the distribution of the product first to Poland, where the registration is currently being completed, and then to Czech Republic. As confirmed by the results of pre-launch activities, Evopharm is confident that Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, can offer to Slovak Healthcare Professionals (“HCPs”) and caregivers a new treatment option to effectively address the wound healing complexity. Local KOLs, involved in an Advisory Board, got particularly impressed from the distinctive physico-chemical properties of this product, able to create the ideal microenvironment to sustain the p

Kao Data Invests in euNetworks High Density Fibre as Part of a North London Artery11.12.2018 09:07Pressemelding

Kao Data, the home of innovation and UK’s leading entrant to the wholesale colocation market, has announced it is working with euNetworks, a Western European bandwidth infrastructure provider. This enables the delivery of high-density fibre and duct to the Kao Data, Harlow based data centre campus north of London. The new infrastructure provides unique routing opportunities, taking advantage of Harlow’s strategic location between core hyperscale campuses in Dublin and Amsterdam. It also offers fast connection to Slough, to the West of London, and Docklands in the East of London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005308/en/ Kao Data Invests in euNetworks High Density Fibre as Part of a North London Artery (Photo: Business Wire) As the UK continues its strong position in the international data centre market, a series of significant investments in high-density fibre routes are underway to support hyperscale d